SITEMAP

• Science
  • Cutting Edge Science
  • Inspiration and Innovation
  • Asthma
    • Cutting Edge Science
      • 2021
        • About Type 2 Inflammation – Asthma
      • Innovation
        • What is your experience with Dupixent in your practice?
        • What gives you confidence that Dupixent improves patients’ quality of life?
      • 2022
        • Consider Dupixent for Asthmatic patients with high EOS
        • Consider Dupixent for Asthmatic patients with OCS use
        • Discover a solution to control mixed Eosinophilic and Allergic Asthma
        • Dupixent® (dupilumab) Mechanism of Action
      • 2023
      • 2024
        • The Vital Role of Lung Function in Asthma Care
        • Severe Asthma Biomarker's
        • Sever Asthmatic patients with OCS
        • Asthma Clinical Remission: The Benchmarks for Eliminating Airway Inflammation and Symptoms
        • Fractional exhaled nitric oxide (Feno)
        • Airway Hyperresponsiveness
          in Asthma
        • ON-TREATMENT ASTHMA REMISSION: MOVING BEYOND CONTROL
      • 2025
        • FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma
        • Mucus Plugging Is a Key Component of Remodeling
          in Asthma, Leading to Fixed Airway Obstruction
        • VESTIGE study
        • VESTIGE Trial Results: Dupilumab in Type 2 Asthma
        • Pediatric Management
        • Assessing Pediatric Lung Function
        • The Role of Mucus Plugging in Asthma and Its Clinical Burden
        • Understanding Airway Obstruction: The Role of Mucus Plugging in Asthmatic Disease
      • 2026
        • IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION
  • Atopic Dermatitis
    • Cutting Edge Science
      • 2021
      • Innovation
      • 2023
      • 2024
      • 2024
  • Bullous Pemphigoid
    • 2025
      • What is Bullous Pemphigoid
      • Patient morbidity and mortality in BP
      • Pathophysiology of Bullous Pemphigoid
      • Treatments and challenges for bullous pemphigoid
      • Considerations for bullous pemphigoid management
  • Cardiovascular
    • Atherothrombosis
      • Cutting Edge Science
        • Innovation
          • 2022
          • 2023
        • 2022
        • 2023
    • Dyslipidemia
      • Cutting Edge Science
        • 2021
        • Innovation
          • Identifying and Treating Patients with High Lipidaemia Risk Post-ACS
          • 2022
        • 2022
    • Hypertension
      • Cutting Edge Science
        • 2023
    • Thrombosis
      • Cutting Edge Science
        • 2021
        • Innovation
          • 2022
          • 2023
        • 2022
          • Changing trends in VTE: Pulmonary Embolism cases on Rise within the Last Decade
          • Benefit of Prophylaxis for High-Risk Surgical Patients
          • Global use of RAM and Thromboprophylaxis in hospitalized patients
          • Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
          • Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery
          • Independent Risk Factors for Venous Thromboembolism
          • Maternity Clot Risk Model to Predict Women at Risk of VTE
          • Prolonged Thromboprophylaxis with LMWH after Abdominal or Pelvic Surgery
          • Risk for Post-operative Venous Thromboembolism in Patients Receiving Enoxaparin Prophylaxis
          • Risk for Pulmonary Embolism Continues Beyond 6 Weeks of Surgery
          • Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent Venous Thromboembolism (VTE)
          • Trends in Pulmonary Embolism-related mortality in Europe
          • Utility of Pregnancy - Adapted Years Algorithm in Diagnosis of Pulmonary Embolism
          • VTE Comparison of Pregnancy - Specific Risk Scoring Systems in Hospitalized Maternity Patients
        • 2023
    • Cutting Edge Science
      • 2021
      • Innovation
  • Chronic Obstructive Pulmonary Disease
    • Cutting Edge Science
      • Innovation
      • 2023
      • 2025
        • Chronic Obstructive Pulmonary Disease (COPD): Disease Burden and Heterogeneity
        • (COPD): Disease Burden and Heterogeneity
        • Type 2 Inflammation in the Pathophysiology of the Lower Airways
        • Clinical Indicators of COPD: A GOLD Guidelines Review
      • 2026
  • Diabetes
    • Cutting Edge Science
      • 2021
      • Innovation
        • Do historical HbA1c values explain glycemic legacy effect of type 2 diabetes?
        • Edition Junior Study - Helping patients with type 1 diabetes (T1D) to find better treatment options
        • The InRange Study
        • Is Premixed Insulin an Effective Treatment for Type 2 Diabetes Uncontrolled by OADs?
        • Summary of SAGE study on Adults with T1DM
        • The SoliRam observational study
        • ATTD 2021: Patients’ profiles for digital tools
        • ATTD 2021: Technology Supporting Initiation, Titration, and Intensification
        • Expert consensus statement on management of older adults with type 2 diabetes (T2D)
        • Glargine 300 use in people with type 2 diabetes who fast during Ramadan
        • Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
        • EVOLUTION: RWE from Saudi Arabia
        • EMPOWER Study in Saudi Arabia
        • 2022
          • Impact of Time-In-Range on Diabetes Management
          • Understanding Time-in-Range: Assessment, Targets, and Benefits for Optimal Glycemic Control
          • What Is Time-in-Range?
      • 2022
        • A narrative review for clinicians on insulin management for Type 2 Diabetes during Ramadan
        • Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.
        • Patient awareness and attainment of goals in Type 2 Diabetes Mellitus: A real-world survey
        • Closed-loop insulin delivery during exercise in people with T1DM
        • Diabetes management during Ramadan
        • Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement
        • Post-exercise hypoglycemia in relation to medication regimen among adults with type 2 diabetes
        • iGlarLixi Enables Safe Ramadan Fasting for Most T2D Patients
        • Recommendations on treatment simplification of complex insulin regimens to improve clinical outcomes in patients with T2DM
      • 2023
        • New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended
      • 2024
        • Inside Diabetes: ATTD Edition | Type 1 Diabetes
        • Need to redefine the treatment paradigm Post OAD
        • Unveiling Significance of Time in Range: Value as key Glycemic Biomarker
        • The Evolving Role of Treatment and Technology in Diabetes Care
        • Time-in-Range: A Key Determinant of Quality of Life
        • SoliD: Redefine Treatment Paradigm Post-OAD
        • Groundbreaking SoliD Study: Comparative Efficacy of iGlarLixi and IDegAsp
        • The ATOS Study: Real-World Study on Effectiveness of Insulin Glargine U300 in the Gulf Region.
        • Why to screen for Autoimmune T1D
        • How to screen for Autoimmune T1D
        • The burden of Autoimmune T1D
        • Understanding Autoimmune T1D disease & Different Stages
      • 2024
        • New Horizon in management of high-risk patients with Diabetes
        • Effective Treatment Simplification
  • Eosinophilic-Esophagitis
    • Cutting Edge Science
      • 2022
        • Understanding eosinophilic esophagitis (EoE)
      • 2024
        • EOE Pediatric - Unmasking the Hidden Symptoms
        • Importance of assessing key disease domains in EOE
      • 2024
        • EoE Pathophysiology
        • EoETaly Guidelines Part-1
        • EoETaly Guidelines Part-2
        • Pediatric EoE: Indicators for Early Diagnosis and Intervention
        • Adaptive Eating Behaviors in EoE
        • Dupilumab in Pediatric EoE: Phase 3 KIDS Study Results
      • Innovation
  • Multiple Myeloma
    • Cutting Edge Science
      • 2022
        • Experts Perspective
        • Myeloma Facts
        • True Cost of Multiple Myeloma
        • Patients Factors & Impacts
      • 2023
  • Multiple Sclerosis
    • Cutting Edge Science
      • 2022
        • MS Updates
        • Why has our brain suddenly become of interest?
        • Cognitive decline – The invisible burden of MS?
      • Innovation
        • 2021
        • 2022
        • 2025
          • Discover the science behind Tolebrutinib: a BTK inhibitor designed to slow MS disability progression by modulating adaptive and innate immunity
          • Inside MS: Explore how BTK drives immune cell activation and CNS damage
      • 2023
      • 2024
        • Learning aRMMs
      • 2025
        • Tolebrutinib Direct Effects on Myeloid Cells in PwMS
    • Smoldering Neuroinflammation
  • Nasal Polyps
    • Cutting Edge Science
      • 2021
        • About Type 2 Inflammation – Nasal Polyps
      • 2022
        • Look beyond the symptoms to identify and manage Patients with Type 2 Inflammation
      • 2023
        • What can biologic treatment do for patients with CRS with nasal polyps?
        • How does Dupixent help recover smell?
        • NPS improvement with Dupixent over time
        • "It really has changed the way I manage our patients"
        • “Smell—we call it the Cinderella of the senses"
        • What does patient empowerment mean for your treatment plan?
        • You can imagine more than 90% of CRSwNP patients losses their ability's of smell
        • Hear from an expert on would you consider a biologic for a Surgery-naïve Patient with CRS with Nasal Polyps?
        • Hear from an expert on Identifying Patients who are appropriate candidates for Biologic treatment
        • Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?
        • Type 2 Inflammation is the underlying cause of CRSwNP in 80% of Patients.
        • Hear From An Expert On Identify Patients Who Are Appropriate Candidates For Biologic Treatment
      • 2024
        • Daily Burden of CRSwNP
      • 2025
        • IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP
        • Loss of Smell Is a Key Symptom in CRSwNP
        • Loss of Smell Improvement in Patients With CRSwNP
        • EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP
  • Neurological Disorders
    • Cutting Edge Science
      • 2022
      • 2023
      • Innovation
  • Prurigo-Nodularis
    • Cutting Edge Science
      • 2022
        • Mechanism of Prurigo Nodularis Disease
        • There is significant unmet need in the management of PN¹
        • Prurigo Nodularis Is A Distinct, Chronic, Neural And Immune- Mediated Skin Disease Characterized By Intense Itch And Nodular Lesions1
        • Type 2 Inflammation may play a role in Prurigo Nodularis Pathophysiology1
      • 2022
        • Practical Approach in Understanding PN Pathophysiology
  • Rare Diseases
    • Cutting Edge Science
      • 2021
      • Innovation
        • Diagnostic Algorithm for Gaucher Disease in Pediatric
        • Professor Moeen Al Sayed video on ASMD
        • Professor Tawfeq Ben Omran video on ASMD
        • Better care for Fabry
        • Gaucher disease awareness month video
        • 2022
          • The Role of Pediatrician in Gaucher Disease
      • 2022
        • How do you know if you or a loved one has ASMD?
        • How is ASMD inherited?
        • MPSI – Endocrinology Case Study
        • What is ASMD?
      • 2023
        • Differential Diagnosis Of Late Onset Pompe Disease (LOPD) and Myotonic Dystrophy Type 1 Through Abdominal Ultrasonography
        • Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease for orthopedists
        • Expert Group Consensus From The Arabian Peninsula On The Diagnosis Of Late Onset Pompe Disease (LOPD)
        • Experts recommendations on Late Onset Pompe Disease (LOPD) differential diagnosis from GCC
        • Prevalence Of LOPD In Patients With Undifferentiated Proximal Myopathy And Undiagnosed Muscle Biopsy
        • Gaucher
      • 2024
        • BIOCHEMICAL DIAGNOSTIC STRATEGY IN FEMALES SUSPECTED OF FABRY DISEASE
        • ROLE OF ECG IN DIFFERENTIAL DIAGNOSIS OF ANDERSON–FABRY DISEASE WITH HCM
        • DIAGNOSING FABRY DISEASE IN CLINICAL PRACTICE
        • Pompe Care Podcast Series
        • Navigating the Pompe Disease Journey
        • Impact of symptoms and risk of ASMD on patients and caregivers
        • Differential diagnostics for ASMD in patients suspected to have GD
        • Consensus Guidelines for the Clinical Management of ASMD
        • What Are the Signs and Symptoms of ASMD?
        • ASMD
        • Legacy Video for Rare Disease Academy
        • Uncover ASMD and GAUCHER
      • 2025
        • Every Moment Matters: Navigating Diagnosis of Fabry Disease
        • Long-term Safety and Efficacy of Avalglucosidase Alfa IN Patients with Late-Onset Pompe Disease (NEO-EXT)
        • Safety and efficacy of Avalglucosidase Alfa versus Alglucosidase Alfa in patints with Late-Onset Pompe Disease (COMET): a phase 3, randomized, multicentral study results
    • Meet a Sanofi Specialist
    • Gaucher
      • Cutting Edge Science
    • Fabry
      • Cutting Edge Science
  • Vaccines
    • Influenza
      • Cutting Edge Science
        • 2021
        • Innovation
          • Sanofi Pasteur at Glance
          • Sanofi Pasteur at Glance
        • 2022
        • 2023
          • Flu and Vaccination
          • Flu in High Risk Population
    • RSV
      • Cutting Edge Science
        • Innovation
        • 2023
          • RSV
          • Burden of Disease
          • RSV History
          • Rattle
          • All Infant Protection
        • 2024
          • RSV Burden in Infants
          • Saudi initiatives on Bronchiolitis Recommendations
        • 2025
          • RSV Burden in Jazan
          • Beyond High-Risk: Expanding RSV Protection for Newborns and Infants
          • New horizon of RSV lower respiratory tract disease LRTD in infants: Reflection on two seasons of prevention
          • Nirsevimab RWD Metanalysis
          • Kuwait taking the lead in RSV protection for all infants in the Middle east
          • Ensuring overall RSV prevention in every individual Dr. Alia Podcast
          • Nirsevimab FAQs
          • Healthcare Utilization and Economic Burden of RSV Infections Among Children Under 5 Years in Saudi Arabia: A MNGHA Facilities Analysis
        • 2026
          • RWE data on Nirsevimab and RSV preF vaccine
    • Mass Gathering
      • Cutting Edge Science
        • 2025
          • Infectious Disease During Mass Gathering
• Patient Support
  • Patient Support Articles
  • Atopic Dermatitis
    • 2022
  • Cardiovascular
  • Diabetes
    • Tools and Resources
      • Clinical and economic value of Soliqua - Pharmacist perspective
      • Pre-Ramadan assessment and Risk calculation for people with diabetes who want to fast during Ramadan
    • 2022
    • 2021
  • Rare Diseases
  • Vaccines
    • RSV
• Products
  • Adacel®
  • Aubagio®
    • Aubagio vs Ofatumumab
  • Beyfortus®
    • International Recommendation
      • Nirsevimab International Recommendation
    • Conferences
      • Implementing Beyfortus successfully
      • Beyfortus®, an innovative immunization
      • Beyfortus in Action ECMMID
      • 2024 RSV International Congress - ESPID
      • 2024 RSV International Congress ECMMID
    • Real World Evidence
      • Implementing Beyfortus successfully (ES)
      • Implementing Beyfortus successfully (FR)
      • Implementing Beyfortus successfully (US)
      • Beyfortus in Action
      • Real World Evidence Impact of universal immunization with Nirsevimab
    • Clinical Experience
      • Nirsevimab : Clinical Experience
  • Cerezyme®
  • Clexane®
    • Surgical Patients
    • Hemodialysis
  • Dupixent®
    • Atopic Dermatitis
    • Dupixent Asthma
    • Nasal Polyps
    • Dr. Ayman Alnaeem’s Very First Dupixent Patient Experience
    • A Message to You from Dr. Ayman AlNaeem
    • How Dupixent Changed Dr. Ayman AlNaeem’s Approach in AD Treatment
    • The Burden of AD through Dr. Ayman Alnaeem’s Expertise/eyes
    • The Burden of AD by Dr. Paula Nelson
    • Dr. Paula Nelson’s Very First Dupixent Patient Experience​
    • Dr. Paula’s insights on treating AD patients with Dupixent
  • Fabrazyme®
    • Quantifying the Effect of Fabrazyme
    • Canadian Fabry Disease Initiative
    • Long Term Renal Function
  • Lemtrada®
  • Myozyme®
  • Praluent®
    • It’s Praluent of Course
      • MACE Reduction
      • Mortality Reduction
      • Patient Friendly
      • Ticks All the Boxes
  • Soliqua®
    • For a Peaceful Ramadan
    • Soli-Simplify Study
    • Soliqua SoliD®
    • Soliqua Easy Start®
    • Soliqua Guidelines®
    • Soliqua Data Set®
    • Soliqua Simplicity®
    • Soliqua Safety®
    • Soliqua®
  • Toujeo®
    • Toujeo for a Peaceful Ramadan
    • Wall of Evidence
    • Toujeo T1DM
      • OneCare
      • Edition Junior
      • UltraFlexi-1
      • Type-1 Meta Analysis
      • Guidelines
    • Toujeo T2DM
      • Deliver-G
      • Guidelines
    • How to Start
    • Toujeo Innovation
      • Toujeo Upgrade to Win
  • Xatral®
• Events
  • Cardiovascular
    • 2021
      • VTE Safety Zone: VTE in general surgery from risk assessment to appropriate thromboprophylaxis
    • 2022
    • 2023
  • Diabetes
    • 2021
    • 2022
      • Nutrition and Insulin management in Ramadan
      • Diabetes Guidelines in Ramadan
      • Innovation of Iglarlexi in Intensification
      • Ultimate Need for Intensification
      • Innovation of Iglarlexi in Intensification
    • 2023
      • Amaryl Safe & Smart: Cardio Safe & Gluco Smart Approach in Diabetes Management
      • Safe & Smart - Dr. Kalra
      • Safe & Smart - Dr. Khudhair
      • Safe & Smart - Dr. Nabil
      • Safe & Smart - Dr. Salah
    • 2024
      • Dia-Tour: Navigating New Destinations in Diabetes Management
  • Rare Diseases
    • 2022
    • 2024
      • Fabry Monitoring Matters Webinar Series
  • Vaccines
    • 2022
  • Multiple Sclerosis
    • 2022
    • 2023
      • The Underlying Biology of Neuroinflammation
    • 2026
      • Advancing the Standard of Care: Addressing Progression in MS
  • Prurigo Nodularis
    • 2022
  • Anti-Infectives
    • 2022
    • 2023
  • Neurological Disorders
    • 2023
      • World Epilepsy Day Podcast Ep. 1
      • World Epilepsy Day Podcast Ep. 2
      • World Epilepsy Day Podcast Ep. 3
    • 2026
      • MS pulse - Tracking the hidden drivers of MS progression
    • 2022
  • Atopic Dermatitis
    • Type II Summit 2025
• Cookie Policy
• Legal Notice
• Privacy Policy
• Sanofi in News
  • 2022
    • Saudi Health Council, Sanofi partner to boost diabetes studies and research in the kingdom
    • Ministry of Health organizes "KiDS" program at Expo 2020 Dubai to promote diabetes awareness at schools
• Search
• Registration